RE:RE:RE:New Corporate Presentation is upAs per mentioned by SPCEO the monthly administration trial's cost will be carried by both companies, not sure about biweekly l am not even sure they do biweekly and just go with monthly.
But it seems the cost to TH is on a pro forma basis directly related to percentage of sales which is good.
Spartrap wrote: Was it known that the Trogarzo's IM study is to be conducted by Thera?
Wonder how much this is going to cost, on top of the two other european trog studies.. (ouch)
scarlet1967 wrote:
For R&D looking through it quickly they added the fast track for PDC and study may proceed for both protocols.
The commercializing strategies seems to have few new additions, note they are saying the Trogarzo market opportunity could be as much as US!
“New Go-to-Market Strategy Underpinned by Sales Force Reorganization and Targeted Patient / Prescriber Education.
Leverage existing localized KOL relationships to capture HIV market opportunities, which could scale to parity with the U.S.
Targeted and frequent educational initiatives to key KOLs, patients and the HIV community.”
SPCEO1 wrote: https://www.theratech.com/wp-content/uploads/2021/03/Corporate-Presentation_Theratehnologies_March-2021.pdf